afatinib + cisplatin + pemetrexed

This combination therapy consists of afatinib (an EGFR tyrosine kinase inhibitor) with the chemotherapy regimen of cisplatin plus pemetrexed. It has been studied in clinical trials for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations. ## Clinical Evidence The LUX-Lung 3 trial was a Phase III study comparing afatinib monotherapy to cisplatin plus pemetrexed in patients with advanced lung adenocarcinoma harboring EGFR mutations[1][4]. While this trial didn't test the three drugs in combination, it provided important comparative data between afatinib alone versus the chemotherapy combination. A Phase II study evaluated afatinib in combination with pemetrexed and carboplatin (rather than cisplatin) in patients with EGFR mutation-positive NSCLC who had become refractory to first-line osimertinib treatment[2]. This combination showed satisfactory efficacy with manageable adverse events, with a 6-month progression-free survival rate of 57.1%[2]. ## Efficacy and Safety When used in combination, these drugs have shown promising efficacy in clinical trials. Common adverse events include: - Gastrointestinal toxicities (diarrhea, appetite loss, nausea) - Hematological toxicities (neutropenia, thrombocytopenia) - Skin reactions (typical of EGFR inhibitors) - Fatigue These adverse events are generally manageable with standard supportive therapies and dose modifications[5]. ## Mechanism of Action This combination leverages multiple mechanisms: - Afatinib: An irreversible ErbB family blocker that targets EGFR mutations - Cisplatin: A platinum-based chemotherapy that causes DNA damage - Pemetrexed: An antifolate that inhibits multiple enzymes involved in purine and pyrimidine synthesis The combination potentially offers enhanced efficacy compared to single-agent therapy, particularly in patients with specific EGFR mutations. ## Development Status This combination has been studied in various phases of clinical trials, primarily for EGFR mutation-positive non-small cell lung cancer. It represents an approach to overcome resistance to EGFR-TKI monotherapy and may offer clinical benefit in specific patient populations.